Jejunostomy-Based Early Enteral Feeding After Esophagectomy

June 15, 2026 updated by: National Taiwan University Hospital

The Study Wonders Whether Early Gastric Force Feeding Can Reduce the Infection Rate and Whether the External Reaction Can Simultaneously Promote the Gastric Motility of the Gastrointestinal Tract Peristalsis Can Reduce the Complications of Postoperative Neck and Wound Anastomosis Leakage, Provide Postoperative Care for Intact Esophagus, and Reduce Postoperative Mortality.

Esophagectomy with reconstruction for esophageal cancer is associated with delayed gastrointestinal recovery and substantial postoperative morbidity. Whether early jejunostomy-based enteral feeding can be safely initiated after esophagectomy remains uncertain.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Esophageal cancer remains a major gastrointestinal malignancy worldwide. For patients with resectable disease, esophagectomy with reconstruction remains the main curative treatment. Although the overall 5-year survival rate of esophageal cancer has historically been poor, often around 10% to 15%, contemporary surgical series have reported 5-year survival rates approaching 40% or higher in selected patients undergoing resection. Even so, esophagectomy remains a high-risk procedure. Despite advances in minimally invasive techniques and perioperative care pathways, postoperative complications such as pulmonary infection, delayed gastrointestinal recovery, and anastomosis-related complications remain common. Postoperative ileus and systemic inflammatory response can prolong intensive care unit (ICU) and hospital stay, increase health care resource utilization, and add substantially to patient burden. Accordingly, optimizing postoperative recovery has become a major priority in contemporary esophageal surgery.

The intestine is increasingly recognized as a key organ in immune and metabolic regulation. Delayed enteral nutrition may lead to intestinal mucosal atrophy, impaired gut barrier function, and bacterial translocation, thereby exacerbating systemic inflammatory responses. Current critical care and clinical nutrition guidelines generally recommend initiation of enteral nutrition within 24 to 48 hours in hemodynamically stable patients to preserve intestinal integrity and reduce the risk of infection. Enhanced recovery after surgery (ERAS) protocols likewise advocate early enteral nutrition as part of strategies to accelerate postoperative recovery. Although previous studies

have suggested that early enteral nutrition may improve gastrointestinal recovery and reduce infectious complications, its clinical value after esophagectomy with reconstruction has not yet been clearly established. Concerns remain regarding possible adverse effects of early feeding on anastomotic healing, gastric emptying, and postoperative respiratory function, and published findings have varied across clinical settings. In particular, the optimal route of nutritional support, whether oral feeding, nasogastric tube feeding, or jejunostomy feeding, remains uncertain, especially with respect to anastomotic integrity, pulmonary complications, and other perioperative outcomes. These uncertainties continue to support further investigation of early enteral nutrition in patients undergoing esophageal cancer surgery.

Against this background, we conducted a randomized controlled trial in patients undergoing esophagectomy with reconstruction for esophageal cancer to compare 2 postoperative enteral nutrition strategies delivered via jejunostomy: initiation within 24 hours after surgery and initiation after the first postoperative bowel movement under conventional care. The primary objective was to determine whether earlier enteral feeding improved gastrointestinal functional recovery after esophagectomy. We also performed exploratory analyses of perioperative laboratory parameters, postoperative complications, and other indicators of early postoperative recovery.

Study Type

Interventional

Enrollment (Actual)

70

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Taiwan
      • Taipei, Taiwan, Taiwan, 100
        • National Taiwan University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Esophagectomy
  • Esophagectomy & reconstruction
  • Esophagotomy
  • Esophageal reconstruction-with gastric tube
  • Esophageal reconstruction-with colon
  • Esophageal reconstruction with small intestine

Exclusion Criteria:

  • Gastrointestinal perforation
  • Postoperative hemorrhage
  • Intestinal obstruction
  • Shock

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Early intestinal force-feeding and drugs to promote gastrointestinal motility
Enteral force feeding with 5% dextrose injection within 24 hours after operation
No Intervention: giving force-feeding after gas or defecation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
gastrointestinal emptying time
Time Frame: up to 72 hours (time of the first bowel movement or exhaust after surgery )
Start timing the first bowel movement or exhaust time after surgery
up to 72 hours (time of the first bowel movement or exhaust after surgery )

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Infection and Inflammation
Time Frame: up to 72 hours
Laboratory parameters included white blood cell count, C-reactive protein (CRP), and procalcitonin measured on postoperative day 0 and postoperative day 3
up to 72 hours
Postoperative complications
Time Frame: up to72 hours (time of the first bowel movement or exhaust after surgery )
Postoperative complications included pneumonia, anastomotic leakage, vocal cord palsy, bloodstream infection, arrhythmia requiring medication control, pleural effusion, pneumothorax, acute lung injury, chylous leakage, postoperative delirium, systemic inflammatory response syndrome (SIRS), and SIRS score.
up to72 hours (time of the first bowel movement or exhaust after surgery )
Nutritional risk
Time Frame: up to 72 hours
Nutritional risk was assessed on postoperative day 3 using the Malnutrition Universal Screening Tool (MUST)
up to 72 hours
Postoperative recovery
Time Frame: up to 60 days
Postoperative recovery measures included length of stay in the intensive care unit, and total hospital length of stay.
up to 60 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 1, 2022

Primary Completion (Actual)

July 8, 2025

Study Completion (Actual)

July 8, 2025

Study Registration Dates

First Submitted

September 6, 2022

First Submitted That Met QC Criteria

June 6, 2023

First Posted (Actual)

June 7, 2023

Study Record Updates

Last Update Posted (Actual)

June 17, 2026

Last Update Submitted That Met QC Criteria

June 15, 2026

Last Verified

July 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • 202205077MIND

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Early-feeding

Clinical Trials on early feeding

3
Subscribe